Bosakitug - Biosion
Alternative Names: Anti-TSLP mAb; BSI-045B; TQC-2731Latest Information Update: 14 Jun 2024
At a glance
- Originator Biosion
- Developer Biosion; Chia Tai Tianqing Pharmaceutical Group
- Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Thymic stromal lymphopoietin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Asthma; Atopic dermatitis; Rhinosinusitis
- Phase I Chronic obstructive pulmonary disease; Hypersensitivity
Most Recent Events
- 11 Jun 2024 Efficacy and adverse event data from the phase II ADAMANT trial for Atopic dermatitis released by Biosion
- 11 Jun 2024 Chia Tai Tianqing Pharmaceutical Group plans a phase II trial for Rhinosinusitis in China (Injection) in June 2024 (NCT06451640)
- 18 Oct 2023 Phase-II clinical trials in Rhinosinusitis in China (SC) (NCT06036927)